

CLAIMS

1. A cell line which expresses on the cell surface TF, MUC1 and glycoporphin.
- 5 2. The cell line of claim 1, wherein said MUC1 is TA-MUC1 and wherein said glycoporphin is asialoglycoporphin.
3. The cell line of claim 1 or 2 which is selected from the group consisting of
 - 10 (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606;
 - (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and
 - (c) subclones of (a) or (b).
- 15 4. The cell line of any one of claims 1 to 3 comprising a vector.
5. The cell line of claim 4, wherein said vector comprises a nucleic acid molecule.
- 20 6. The cell line of claim 5, wherein said nucleic acid molecule encodes at least one polypeptide of a polypeptide selected from the group consisting of a cytokine, MHC class I molecule, MHC class II molecule and costimulatory molecule, T cell epitope or multimers thereof, tumour antigen, hormone, sexual hormone, adjuvant, antibody or other molecules or fragments thereof
- 25 having biological activity or any combination thereof.
7. A lysate of the cell line of any one of claims 1 to 6.
- 30 8. A molecule or mixture of molecules obtained of any one of claims 1 to 7.
9. Dendritic cells loaded with the lysate, a molecule or a mixture of molecules of claim 8 .

10. Dendritic cells co-incubated or fused with cells of any one of the claims 1 to 6.
- 5 11. A composition comprising the cell line of any one of claims 1 to 6, the lysate of claim 7, the molecule or mixture of molecules of claim 8, or the dendritic cells of claim 9 or 10.
12. The composition of claim 11, which is a pharmaceutical composition.
- 10 13. The composition of claim 11, which is a vaccine composition.
14. The pharmaceutical composition of claim 12 or the vaccine composition of claim 13, further comprising a heterologous cell.
- 15 15. The pharmaceutical composition of claim 12 or 14 or the vaccine composition of claim 13 or 14 further comprising a pharmaceutically acceptable carrier and/or an adjuvant.
- 20 16. The dendritic cells of claim 9 or 10 or the composition of claim 11, wherein said dendritic cells are immature.
17. The dendritic cells of claim 9 or 10 or the composition of claim 11, wherein said dendritic cells are mature.
- 25 18. A method for the production of a vaccine composition comprising the step of combining a cell line of any one of claims 1 to 6 or the lysate of claim 7 or a molecule or a mixture of molecules of claim 8 with an adjuvant and/or with the dendritic cells of claim 9, 10, 16 or 17.
- 30 19. A method for the production of a pharmaceutical composition comprising the step of combining a cell line of any one of claims 1 to 6 and/or the lysate of claim 5 or a molecule or a mixture of molecules of claim 8 and/or the dendritic cells of any one of claims 9, 10, 16 or 17 with a pharmaceutically acceptable carrier.

20. A method for the treatment or prevention of cancers and/or tumourous diseases comprising administering a therapeutically or prophylactically effective amount of the effective amount of the cell line of any one of claims 1 to 6 and/or the lysate of claim 7 or a molecule or a mixture of molecules of claim 6 and/or the dendritic cells of any one of claims 9, 10, 16 or 17, the pharmaceutical composition or vaccine composition of any one of claims 12 to 15 or the dendritic cells of claim 9, 10, 16 or 17.
21. Use of the cell line of any one of claims 1 to 6, the lysate of claim 7, a molecule or mixture of molecules of claim 8, or the dendritic cells of claim 9 or 10, 16 or 17 for the preparation of a pharmaceutical or vaccine composition for the treatment or prevention of cancers and/or tumourous diseases.
22. The method of claim 20 or the use of claim 21, wherein said cancer or tumourous disease is a cancer of the head and neck, lung, mediastinum, gastrointestinal tract, genitourinary system, gynaecological system, breast, endocrine system, skin, childhood, unknown primary site or metastatic cancer, a sarcoma of the soft tissue and bone, a mesothelioma, a melanoma, a neoplasm of the central nervous system, a lymphoma, a leukaemia, a paraneoplastic syndrome, a peritoneal carcinomatosis, a immunosuppression-related malignancy and/or metastatic cancer.